SKK
VKTX icon

Shepherd Kaplan Krochuk’s Viking Therapeutics VKTX Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,570
Closed -$55K – 277
2017
Q4 		$55K Sell
13,570
-62,000
-82% -$180K 0.03% 235
2017
Q3 		$136K Sell
75,570
-10,000
-12% -$11.4K 0.11% 172
2017
Q2 		$92K Sell
85,570
-18,408
-18% -$23.4K 0.05% 202
2017
Q1 		$152K Buy
103,978
+9,000
+9% +$12.6K 0.08% 179
2016
Q4 		$113K Buy
94,978
+61,978
+188% +$69.9K 0.03% 216
2016
Q3 		$46K Buy
+33,000
New +$43.7K 0.01% 358

Other funds holding VKTX

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Shepherd Kaplan Krochuk's VKTX Position: Q1 2018 in Review

Shepherd Kaplan Krochuk sold out of Viking Therapeutics (VKTX) in Q1 2018, closing a stake of 13,570 shares — an estimated $55K sold.

Shepherd Kaplan Krochuk first reported a position in VKTX in Q3 2016 and held it in 6 quarters. The position peaked at $152K in Q1 2017. 66 funds tracked by Wall St. Rank hold VKTX as of Q1 2018.

  • Shepherd Kaplan Krochuk reported no remaining Viking Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 13,570 Viking Therapeutics shares in Q1 2018, an estimated $55K.
  • Shepherd Kaplan Krochuk first reported a position in Viking Therapeutics in Q3 2016 and held it in 6 quarters.
  • Shepherd Kaplan Krochuk's Viking Therapeutics position peaked at $152K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2018.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2018, filed 11 May 2018.